-
公开(公告)号：US20240208992A1
公开(公告)日：2024-06-27
申请号：US18550883
申请日：2021-07-12
发明人： Martin BOLLI , Christine BROTSCHI , Malgorzata COMMANDEUR , John GATFIELD , Thierry KIMMERLIN , Hervé SIENDT , Jasper SPRINGER , Clemens WAGNER , Anita WEGERT , Jodi T. WILLIAMS
IPC分类号： C07D498/04 , A61K31/4745
CPC分类号： C07D498/04 , A61K31/4745
摘要： The present invention relates to macrocyclic compounds of Formula (I)
wherein Ar1, Ar2, R1, R2, R3, R4, and X are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as modulators of CFTR.-
公开(公告)号：US20240109930A1
公开(公告)日：2024-04-04
申请号：US18548833
申请日：2022-03-02
发明人： Martin BOLLI , John GATFIELD , Corinna GRISOSTOMI , Lubos REMEN , Christoph SAGER , Cornelia ZUMBRUNN
摘要： The present invention relates to Galectin-3 inhibitors of Formula (I) and pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds, and their medical uses.
-
![2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES](/abs-image/US/2023/06/22/US20230192708A1/abs.jpg.150x150.jpg)
公开(公告)号：US20230192708A1
公开(公告)日：2023-06-22
申请号：US18084911
申请日：2022-12-20
发明人： Sylvie FROIDEVAUX , Francis HUBLER , Mark MURPHY , Dorte RENNEBERG , Simon STAMM
IPC分类号： C07D487/04
CPC分类号： C07D487/04
摘要： The present invention relates to derivatives of formula (I)
wherein Ring A, X, Y, Z, RA, R1, R2, R3 and R4 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as C5a receptor modulators.-
公开(公告)号：US20230165859A1
公开(公告)日：2023-06-01
申请号：US18058873
申请日：2022-11-27
发明人： Heinz FRETZ , Isabelle LYOTHIER , Julien POTHIER , Sylvia RICHARD-BILDSTEIN , Thierry SIFFERLEN
IPC分类号： A61K31/506 , A61P35/00 , A61K45/06 , C07D403/12
CPC分类号： A61K31/506 , A61P35/00 , A61K45/06 , C07D403/12
摘要： The present invention relates to derivatives of formula (I)
wherein R1, and R2 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptor EP2.-
![PHARMACEUTICAL COMPOSITIONS COMPRISING N-[1-(5-CYANO-PYRIDIN-2-YLMETHYL)-1H-PYRAZOL-3-YL]-2-[4-(1-TRIFLUOROMETHYL-CYCLOPROPYL)-PHENYL]-ACETAMIDE](/abs-image/US/2023/02/16/US20230047102A1/abs.jpg.150x150.jpg)
公开(公告)号：US20230047102A1
公开(公告)日：2023-02-16
申请号：US17786965
申请日：2020-11-02
发明人： Michael Ambuehl , Nasser Benniou , Frantz Elbaz , Frederic Heyer , Ibrahima Sow
IPC分类号： A61K31/4439 , A61K47/22 , A61K47/32 , A61K47/38 , A61K47/36 , A61K47/02 , A61K47/12 , A61P25/08
摘要： The present invention relates to solid pharmaceutical compositions comprising N-[1-(5-cyano-pyridin-2−ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide or pharmaceutically acceptable salt thereof. The invention further relates to methods for manufacturing said compositions and their uses for the treatment or prevention of diseases and disorders linked to T-type calcium channels such as epilepsy.
-
公开(公告)号：US20230045939A1
公开(公告)日：2023-02-16
申请号：US17296194
申请日：2019-11-22
发明人： Madhu EMMADI , Marilda P. LISBOA , Daniel KNOPP , Bopanna MONNANDA , Arne VON BONIN , Claney Lebev PEREIRA
摘要： The present invention relates to a synthetic saccharide of general formulate (I) that is related to Clostridium difficile PS-II cell-surface polysaccharide and conjugate thereof. Said synthetic saccharide, said conjugate and pharmaceutical composition containing said synthetic saccharide or said conjugate are useful for prevention and/or treatment of diseases associated with Clostridium difficile. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Clostridium difficile bacteria.
-
![CRYSTALLINE FORM OF THE COMPOUND (S)-3-{4-[5-(2-CYCLOPENTYL-6-METHOXY-PYRIDIN-4-YL)-[1,2,4]OXADIAZOL-3-YL]-2-ETHYL-6-METHYL-PHENOXY}-PROPANE-1,2-DIOL](/abs-image/US/2023/01/05/US20230002365A1/abs.jpg.150x150.jpg)
公开(公告)号：US20230002365A1
公开(公告)日：2023-01-05
申请号：US17810545
申请日：2022-07-01
IPC分类号： C07D413/04 , A61P37/00 , A61K31/047 , A61K31/4245 , A61K31/44
摘要： The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.
-
公开(公告)号：US20220324847A1
公开(公告)日：2022-10-13
申请号：US17634512
申请日：2020-08-14
发明人： Martin BOLLI , John GATFIELD , Corinna GRISOSTOMI , Lubos REMEN , Christoph SAGER , Cornelia ZUMBRUNN
IPC分类号： C07D405/04 , C07D405/14 , C07D417/14 , C07D413/14 , C07D409/14
摘要： The present invention relates to compounds of Formula (I) wherein Ar1, Ar2, L, n, and R1 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.
-
公开(公告)号：US20220315619A1
公开(公告)日：2022-10-06
申请号：US17633895
申请日：2020-08-07
发明人： Martin BOLLI , Daniel BUR , John GATFIELD , Corinna GRISOSTOMI , Lubos REMEN , Cornelia ZUMBRUNN
IPC分类号： C07H19/056
摘要： The present invention relates to compounds of Formula (I) wherein Ar1, Ar2, R1a, R1b, and R2 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.
-
公开(公告)号：US20220265658A1
公开(公告)日：2022-08-25
申请号：US17625522
申请日：2020-07-08
发明人： Michael AMBUEHL , Elvire FOURNIER , Amandine FRAICHARD , Sylvie FROIDEVAUX , Oliver GEISELER , Charlyse HERRMANN , Francis HUBLER , Mark MURPHY , Dorte RENNEBERG , Simon STAMM , Markus VON RAUMER
摘要： The invention relates to pharmaceutical compositions, which are self-emulsifying, self-microemulsifying, or self-nanoemulsifying in aqueous medium, comprising the compound: 2-(2,2-Difluoro-propyl)-5-[1-(2-fluoro-6-methyl-phenyl)-piperidin-4-yl]-7-(2-trifluoromethyl-benzyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-d]pyrimidin-6-one and a mixture of excipients comprising one or more lipophilic excipient(s); one or more hydrophilic surfactant(s); and optionally one or more hydrophilic co-solvent(s). The invention further relates to a crystalline form of said compound, and its use for the preparation of the present compositions. The invention further relates to pharmaceutical uses of the compositions for the prevention/prophylaxis or treatment of diseases and disorders related to pathogenic events associated with elevated levels of C5a and/or with C5aR activation.
-
-
-
-
-
-
-
-
-
搜索结果
119 条记录 (耗时 0.025 秒)
